Ismail Gögenur

Quick facts

Phase 2 pipeline

• 1 Cycle of Pembrolizumab
• Additional Cycle of Pembrolizumab · Oncology
  Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ismail Gögenur portfolio CI brief
• Ismail Gögenur pipeline updates RSS

Related

• Sector hub: All tracked pharma companies